• PDF: Delivered by email usually within 48 UK business hours.

Qiagen N.V.
Market Share Analysis

  • Publication Date:September 2010
  • Publisher:GlobalData
  • Product Type: Report
  • Pages:164

Qiagen N.V. Market Share Analysis

Qiagen N.V. Market Share Analysis

Summary

GlobalData's new report, ""Qiagen N.V. Market Share Analysis"" provides in-depth information on Qiagen's market position in the different medical equipment markets it operates in. The report provides Qiagen's market share information in two key market categories - Genetic Testing and Infectious Immunology. The report also provides data and information on the overall competitive landscape of the markets, the company operates in. The report is supplemented with global corporate-level profile with information on the company's business segments, major products and services, competitors, locations and subsidiaries, financial deals and other key developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

  • Global company shares (in Revenues) information for the key markets Qiagen operates in - In Vitro Diagnostics.
  • Qiagen's company shares (in Revenues) information for all the key countries the company has presence in - United States, Canada, UK, Germany, France, Italy, Spain, Japan, China, India, and Australia.
  • Qiagen's company shares (in Revenues) information for all the key market categories the company has presence in - Genetic Testing and Infectious Immunology.
  • All the key data-points are for 2009 and cover all the key regions - North America, Europe, Asia Pacific (APAC), and Middle East and Africa (MEA).
  • Global corporate-level profile with information on the company's business segments, major products and services, competitors, and locations and subsidiaries.
  • The company profile is also supplemented with a SWOT Analysis with in-depth information and analysis of the company's value proposition and the business climate it operates in.
  • Comprehensive coverage of the latest financial deals involving the company and its subsidiaries, if any - Mergers & Acquisitions (M&A), Asset Transactions, PE/VC, Equity Offerings, Debt Offerings, and Partnerships.

Reasons to buy

  • Develop sales and marketing strategies by identifying who-stands-where in the markets, Qiagen operates in.
  • Plan your competition strategies by identifying the company's shares in the markets and geographic regions it operates in.
  • Design your own inorganic growth and business-collaboration strategies by understanding the financial deals your competitors are involved in.
  • Advance your understanding of the competitive landscape and the competitors by leveraging on the data and information provided in the report.
  • Support your overall business strategies by leveraging on the key data and information provided in the report, which includes but not limited to Qiagen's market positions.

This report covers the following industry codes:
SIC Code: 3841
NAICS Code: 332994

  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
    • 2.1 What Is This Report About?
  • 3 Definitions of Markets/Categories Covered
    • 3.1 In Vitro Diagnostics
    • 3.1.1 Clinical Chemistry
    • 3.1.2 Genetic Testing
    • 3.1.3 Haematology
    • 3.1.4 Histology And Cytology
    • 3.1.5 Immuno Chemistry
    • 3.1.6 Infectious Immunology
    • 3.1.7 Microbiology Culture
  • 4 Company Snapshot
    • 4.1 Key Information
    • 4.2 Company Overview
    • 4.3 Financial Performance
    • 4.4 SWOT Snapshot
    • 4.5 Business Overview
    • 4.6 Major Products and Services
    • 4.6.1 Overview
  • 5 History
  • 6 SWOT Analysis
    • 6.1 Overview
    • 6.2 Qiagen N.V. Strengths
    • 6.2.1 Strong Research and Development Activities
    • 6.2.2 Wide Geographical Presence
    • 6.2.3 Broad Product Portfolio
    • 6.2.4 Strong Financial Performance
    • 6.3 Qiagen N.V. Weaknesses
    • 6.3.1 Long Term Debts
    • 6.3.2 Pending Litigations
    • 6.4 Qiagen N.V. Opportunities
    • 6.4.1 Biotech Focus
    • 6.4.2 Potential Market
    • 6.4.3 Market Growth in Emerging Economies
    • 6.4.4 Inorganic Growth Strategy
    • 6.4.5 New Product Launches
    • 6.5 Qiagen N.V. Threats
    • 6.5.1 Stringent Government Regulations
    • 6.5.2 Competitive Landscape
    • 6.5.3 Rapid Technological Change
    • 6.5.4 Cost Containment Pressures
  • 7 Competitors
  • 8 Competitive Landscape
    • 8.1 In Vitro Diagnostics, Global, Company Share (%), 2009
  • 9 Qiagen N.V. Medical Equipment Market Share Analysis
    • 9.1 Qiagen N.V., In Vitro Diagnostics, Global, Market Share (2009)
    • 9.2 Qiagen N.V., Asia-Pacific, Market Share (2009)
    • 9.3 Qiagen N.V., Europe, Market Share (2009)
    • 9.4 Qiagen N.V., Middle East and Africa, Market Share (2009)
    • 9.5 Qiagen N.V., North America, Market Share (2009)
    • 9.6 Qiagen N.V., South and Central America, Market Share (2009)
  • 10 Qiagen N.V. Medical Equipment Market Share Analysis by Category
    • 10.1 Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (2009)
    • 10.2 Qiagen N.V., Asia-Pacific, Category Revenue Share (2009)
    • 10.2.1 Qiagen N.V., Australia, Category Revenue Share (2009)
    • 10.2.2 Qiagen N.V., China, Category Revenue Share (2009)
    • 10.2.3 Qiagen N.V., India, Category Revenue Share (2009)
    • 10.2.4 Qiagen N.V., Japan, Category Revenue Share (2009)
    • 10.2.5 Qiagen N.V., Other Asia-Pacific, Category Revenue Share (2009)
    • 10.3 Qiagen N.V., Europe, Category Revenue Share (2009)
    • 10.3.1 Qiagen N.V., France, Category Revenue Share (2009)
    • 10.3.2 Qiagen N.V., Germany, Category Revenue Share (2009)
    • 10.3.3 Qiagen N.V., Italy, Category Revenue Share (2009)
    • 10.3.4 Qiagen N.V., Spain, Category Revenue Share (2009)
    • 10.3.5 Qiagen N.V., United Kingdom, Category Revenue Share (2009)
    • 10.3.6 Qiagen N.V., Other Europe, Category Revenue Share (2009)
    • 10.4 Qiagen N.V., Middle East and Africa, Category Revenue Share (2009)
    • 10.5 Qiagen N.V., North America, Category Revenue Share (2009)
    • 10.5.1 Qiagen N.V., Canada, Category Revenue Share (2009)
    • 10.5.2 Qiagen N.V., United States, Category Revenue Share (2009)
    • 10.6 Qiagen N.V., South and Central America, Category Revenue Share (2009)
    • 10.6.1 Qiagen N.V., Brazil, Category Revenue Share (2009)
    • 10.6.2 Qiagen N.V., Other South and Central America, Category Revenue Share (2009)
  • 11 Key Employees
  • 12 Key Employee Biographies
  • 13 Company Statement
  • 14 Locations And Subsidiaries
    • 14.1 Head Office
    • 14.2 Other Locations & Subsidiaries
  • 15 Financial Deals Landscape
    • 15.1 Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010
  • 16 Qiagen N.V. Detailed Deal Summary
    • 16.1 Asset Purchase
    • 16.1.1 QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business
    • 16.1.2 QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology
    • 16.2 Private Equity
    • 16.2.1 QIAGEN Sells Synthetic DNA Business Unit
    • 16.3 Partnerships
    • 16.3.1 QIAGEN Enters Into An Agreement With Genome Diagnostics
    • 16.3.2 QIAGEN Enters Into Distribution Agreement With Celera
    • 16.3.3 QIAGEN Forms Joint Venture With Bio One Capital
    • 16.3.4 Qiagen And Whatman Enter Into Distribution Agreement
    • 16.3.5 QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement
    • 16.3.6 QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics
    • 16.3.7 Beckman Coulter Enters Into Co-Marketing Agreement With QIAGEN
    • 16.3.8 Veridex Enters Into Co-Marketing Agreement With QIAGEN
    • 16.3.9 Abbott Laboratories Signs An Agreement With Artus
    • 16.3.10 Roche Enters Into Licensing Agreement With QIAGEN
    • 16.3.11 QIAGEN Enters Into Licensing Agreement With Johns Hopkins University
    • 16.3.12 QIAGEN Enters Into An Agreement With Roche And Idaho Technology
    • 16.3.13 HandyLab Enters Into An Agreement With Qiagen
    • 16.3.14 QIAGEN Extends Its Agreement With Epigenomics
    • 16.4 Equity Offering
    • 16.4.1 QIAGEN Completes Private Placement Of Its Common Stock For $640 Million
    • 16.4.2 QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million
    • 16.4.3 QIAGEN Completes Private Placement Of Notes Due 2024 For $150 Milion
    • 16.5 Acquisition
    • 16.5.1 QIAGEN Completes Acquisition Of ESE
    • 16.5.2 QIAGEN Completes Acquisition Of SABiosciences
    • 16.5.3 QIAGEN Completes Acquisition Of DxS
    • 16.5.4 QIAGEN Completes Acquisition Of Explera
    • 16.5.5 QIAGEN Acquires Corbett Life Science
    • 16.5.6 QIAGEN Acquires Digene
    • 16.5.7 QIAGEN Acquires eGene
    • 16.5.8 QIAGEN Acquires Genaco Biomedical Products
    • 16.5.9 QIAGEN Acquires Shenzhen PG Biotech
    • 16.5.10 QIAGEN Acquires Tianwei
    • 16.5.11 QIAGEN Acquires QIAGEN Hamburg
    • 16.5.12 QIAGEN Acquires Artus
  • 17 Recent Developments
    • 17.1 Strategy And Business Planning
    • 17.1.1 Sep 08, 2009: Qiagen Inaugurates New Asia Headquarters In Shanghai
    • 17.1.2 Jun 16, 2009: Qiagen, Linkmed Sign Agreement To Transfer Distribution Rights
    • 17.1.3 Feb 22, 2008: Qiagen Opens New Service Solutions Center In Singapore
    • 17.2 Financial Announcements
    • 17.2.1 Aug 09, 2010: Qiagen Reports Net Income Of $38.52 Million In Q2 2010
    • 17.2.2 May 03, 2010: Qiagen Reports Net Income Of $33 Million In Q1 2010
    • 17.2.3 Feb 08, 2010: Qiagen Reports Net Income Of $137.7 Million In 2009
    • 17.2.4 Nov 09, 2009: Qiagen Reports Net Income Of $37.7 Million In Q3 2009
    • 17.2.5 Aug 10, 2009: Qiagen Reports Net Income Of $30.9 Million In Q2 2009
    • 17.2.6 May 04, 2009: Qiagen Posts Profit Of $24.6 Million In Q1 2009
    • 17.2.7 Feb 09, 2009: Qiagen Reports Preliminary 2008 Results
    • 17.2.8 Nov 10, 2008: Qiagen Reports 3Q 2008 Results
    • 17.2.9 Aug 04, 2008: Qiagen Reports 2Q 2008 Results
    • 17.2.10 May 05, 2008: Qiagen Reports Q1 2008 Results
    • 17.2.11 Feb 11, 2008: Qiagen Reports Q4 2007 Results
    • 17.3 Research And Development
    • 17.3.1 Jan 12, 2009: QIAGEN led-Consortium Launches Project To Improve In-Vitro Diagnostics
    • 17.3.2 Dec 03, 2007: QIAGEN, Bio*One Establish Dx Assays
    • 17.4 Corporate Communications
    • 17.4.1 Dec 14, 2009: Qiagen Added To NASDAQ-100 Index
    • 17.4.2 Jan 26, 2009: QIAGEN Appoints New President For QIAGEN Japan
    • 17.4.3 Jan 19, 2009: QIAGEN Appoints New Head, Global Regulatory Affairs
    • 17.4.4 May 13, 2008: Qiagen Appoints VP, Molecular Diagnostic Sales For EMEAA
    • 17.5 Legal and Regulatory
    • 17.5.1 Apr 01, 2009: Qiagen Announces CAFC Rejects Third Wave
    • 17.5.2 Jan 22, 2009: QIAGEN And Applied Biosystems Settle All Disputes Over Real-Time PCR Thermal Cycler Patents
    • 17.6 Product News
    • 17.6.1 Sep 01, 2010: QIAGEN Launches QIAsymphony RGQ System For Molecular Diagnostics
    • 17.6.2 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control
    • 17.6.3 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test
    • 17.6.4 Jan 25, 2010: Qiagen Introduces QIAsymphony AS
    • 17.6.5 Jan 18, 2010: Study Finds QIAGEN's Digene HPV Test Effective In Preventing Invasive Cervical Cancer
    • 17.6.6 Sep 10, 2009: QIAGEN Introduces Artus Influenza/H1 RG/LC RT-PCR Kit
    • 17.6.7 Jun 03, 2009: QIAGEN's Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis
    • 17.6.8 Apr 28, 2009: QIAGEN Provides Screening Tests For Swine Flu Virus
    • 17.6.9 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap
    • 17.6.10 Mar 06, 2009: QIAGEN Supports Cervical Cancer Screening For Underprivileged Chinese Women
    • 17.6.11 Nov 10, 2008: QIAGEN Introduces CE-marked Molecular Assay For The Cancer Biomarker K-ras
    • 17.6.12 Aug 19, 2008: QIAGEN Unveils Diagnostic Assay In The EU To Detect Genetic Variation Causing Adverse Reactions In AIDS Patients
    • 17.6.13 Feb 14, 2008: QIAGEN And Center For Molecular Medicine Create Research Collaboration For Molecular Diagnostic Markers For Breast Cancer, Other Women's Health Issues
    • 17.6.14 May 11, 2007: Digene Research At Clinical Virology Symposium Shows Strides In Multiplex Genotyping Technology Development
    • 17.6.15 Apr 19, 2007: Digene Announces Exclusive Marketing and Distribution Agreement with Asuragen, Inc. for Signature Cystic Fibrosis Screening Products
    • 17.7 Product Approvals
    • 17.7.1 Jul 06, 2010: Qiagen Receives CE Mark For careHPV Test
    • 17.7.2 Jun 03, 2009: QIAGEN's Next Generation Molecular Diagnostic Receives CE Mark Approval For KRAS Analysis
    • 17.8 Clinical Trials
    • 17.8.1 Jul 12, 2010: QIAGEN Announces digene HPV Test Shows Successful Cervical Cancer Control
    • 17.8.2 Jan 18, 2010: Study Finds QIAGEN's Digene HPV Test Effective In Preventing Invasive Cervical Cancer
    • 17.8.3 Apr 01, 2009: Landmark Study Shows Significant Reduction In Death Rate From Cervical Cancer With The Digene HPV Test Compared To Other Methods Including Pap
    • 17.9 Other Significant Developments
    • 17.9.1 Mar 08, 2010: QIAGEN Extends Support Of Cervical Cancer Screening Program For Underprivileged Chinese Women
    • 17.9.2 May 28, 2009: Qiagen Awards Development Contract To Plexus
    • 17.9.3 May 28, 2009: Qiagen To Supply Molecular Screening Solutions To Increase Safety Of Blood Donations In Brazil
    • 17.9.4 Sep 22, 2008: Osmetech Signs Agreement With Qiagen For QIAplex-Based Respiratory Viral Molecular Test
    • 17.9.5 Sep 18, 2008: Qiagen CEO To Present At UBS Conference
  • 18 Appendix
    • 18.1 Research Methodology
    • 18.2 Secondary Research
    • 18.3 Primary Research
    • 18.4 Models
    • 18.5 Forecasts
    • 18.6 Expert Panels
    • 18.7 GlobalData Consulting
    • 18.8 Currency Conversion
    • 18.9 Contact Us
    • 18.10 Disclaimer
  • 1.1 List of Tables
    • Table 1: Qiagen N.V., Key Facts, 2009
    • Table 2: Qiagen N.V., SWOT Analysis, 2009
    • Table 3: In Vitro Diagnostics, Global, Company Share by Revenue ($m), 2009
    • Table 4: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%), 2009
    • Table 5: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%), 2009
    • Table 6: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%), 2009
    • Table 7: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%), 2009
    • Table 8: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%), 2009
    • Table 9: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%), 2009
    • Table 10: Qiagen N.V., In Vitro Diagnostics, Global, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 11: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 12: Qiagen N.V., In Vitro Diagnostics, Australia, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 13: Qiagen N.V., In Vitro Diagnostics, China, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 14: Qiagen N.V., In Vitro Diagnostics, India, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 15: Qiagen N.V., In Vitro Diagnostics, Japan, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 16: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 17: Qiagen N.V., In Vitro Diagnostics, Europe, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 18: Qiagen N.V., In Vitro Diagnostics, France, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 19: Qiagen N.V., In Vitro Diagnostics, Germany, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 20: Qiagen N.V., In Vitro Diagnostics, Italy, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 21: Qiagen N.V., In Vitro Diagnostics, Spain, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 22: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 23: Qiagen N.V., In Vitro Diagnostics, Other Europe, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 24: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 25: Qiagen N.V., In Vitro Diagnostics, North America, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 26: Qiagen N.V., In Vitro Diagnostics, Canada, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 27: Qiagen N.V., In Vitro Diagnostics, United States, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 28: Qiagen N.V., In Vitro Diagnostics, South and Central America, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 29: Qiagen N.V., In Vitro Diagnostics, Brazil, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 30: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Revenue ($m) and Market Share (%) by Category, 2009
    • Table 31: Qiagen N.V., Key Employees
    • Table 32: Qiagen N.V., Subsidiaries
    • Table 33: Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010
    • Table 34: Qiagen N.V., Deals Summary, 2005 to YTD 2010
    • Table 35: QIAGEN Completes Acquisition Of Molecular Diagnostics Distribution Business
    • Table 36: QIAGEN Completes Acquisition Of Distribution Business From Diagnostic Technology
    • Table 37: QIAGEN Sells Synthetic DNA Business Unit
    • Table 38: QIAGEN Enters Into An Agreement With Genome Diagnostics
    • Table 39: QIAGEN Enters Into Distribution Agreement With Celera
    • Table 40: QIAGEN Forms Joint Venture With Bio One Capital
    • Table 41: Qiagen And Whatman Enter Into Distribution Agreement
    • Table 42: QIAGEN And Pathway Diagnostics Enter Into Co-Marketing Agreement
    • Table 43: QIAGEN Enters Into Distribution Agreement With Osmetech Molecular Diagnostics
    • Table 44: Beckman Coulter Enters Into Co-Marketing Agreement With QIAGEN
    • Table 45: Veridex Enters Into Co-Marketing Agreement With QIAGEN
    • Table 46: Abbott Laboratories Signs An Agreement With Artus
    • Table 47: Roche Enters Into Licensing Agreement With QIAGEN
    • Table 48: QIAGEN Enters Into Licensing Agreement With Johns Hopkins University
    • Table 49: QIAGEN Enters Into An Agreement With Roche And Idaho Technology
    • Table 50: HandyLab Enters Into An Agreement With Qiagen
    • Table 51: QIAGEN Extends Its Agreement With Epigenomics
    • Table 52: QIAGEN Completes Private Placement Of Its Common Stock For $640 Million
    • Table 53: QIAGEN Completes Private Placement Of Notes Due 2026 For $300 Million
    • Table 54: QIAGEN Completes Private Placement Of Notes Due 2024 For $150 Milion
    • Table 55: QIAGEN Completes Acquisition Of ESE
    • Table 56: QIAGEN Completes Acquisition Of SABiosciences
    • Table 57: QIAGEN Completes Acquisition Of DxS
    • Table 58: QIAGEN Completes Acquisition Of Explera
    • Table 59: QIAGEN Acquires Corbett Life Science
    • Table 60: QIAGEN Acquires Digene
    • Table 61: QIAGEN Acquires eGene
    • Table 62: QIAGEN Acquires Genaco Biomedical Products
    • Table 63: QIAGEN Acquires Shenzhen PG Biotech
    • Table 64: QIAGEN Acquires Tianwei
    • Table 65: QIAGEN Acquires QIAGEN Hamburg
    • Table 66: QIAGEN Acquires Artus
    • Table 67: USD to Local Currency, Average Exchange Rate 2009
  • 1.2 List of Figures
    • Figure 1: In Vitro Diagnostics, Global, Company Share (%), 2009
    • Figure 2: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%), 2009
    • Figure 3: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%), 2009
    • Figure 4: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%), 2009
    • Figure 5: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Market Share (%), 2009
    • Figure 6: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%), 2009
    • Figure 7: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%), 2009
    • Figure 8: Qiagen N.V., In Vitro Diagnostics, Global, Category Revenue Share (%), 2009
    • Figure 9: Qiagen N.V., In Vitro Diagnostics, Global, Market Share (%) by Category, 2009
    • Figure 10: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Category Revenue Share (%), 2009
    • Figure 11: Qiagen N.V., In Vitro Diagnostics, Asia-Pacific, Market Share (%) by Category, 2009
    • Figure 12: Qiagen N.V., In Vitro Diagnostics, Australia, Category Revenue Share (%), 2009
    • Figure 13: Qiagen N.V., In Vitro Diagnostics, Australia, Market Share (%) by Category, 2009
    • Figure 14: Qiagen N.V., In Vitro Diagnostics, China, Category Revenue Share (%), 2009
    • Figure 15: Qiagen N.V., In Vitro Diagnostics, China, Market Share (%) by Category, 2009
    • Figure 16: Qiagen N.V., In Vitro Diagnostics, India, Category Revenue Share (%), 2009
    • Figure 17: Qiagen N.V., In Vitro Diagnostics, India, Market Share (%) by Category, 2009
    • Figure 18: Qiagen N.V., In Vitro Diagnostics, Japan, Category Revenue Share (%), 2009
    • Figure 19: Qiagen N.V., In Vitro Diagnostics, Japan, Market Share (%) by Category, 2009
    • Figure 20: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Category Revenue Share (%), 2009
    • Figure 21: Qiagen N.V., In Vitro Diagnostics, Other Asia-Pacific, Market Share (%) by Category, 2009
    • Figure 22: Qiagen N.V., In Vitro Diagnostics, Europe, Category Revenue Share (%), 2009
    • Figure 23: Qiagen N.V., In Vitro Diagnostics, Europe, Market Share (%) by Category, 2009
    • Figure 24: Qiagen N.V., In Vitro Diagnostics, France, Category Revenue Share (%), 2009
    • Figure 25: Qiagen N.V., In Vitro Diagnostics, France, Market Share (%) by Category, 2009
    • Figure 26: Qiagen N.V., In Vitro Diagnostics, Germany, Category Revenue Share (%), 2009
    • Figure 27: Qiagen N.V., In Vitro Diagnostics, Germany, Market Share (%) by Category, 2009
    • Figure 28: Qiagen N.V., In Vitro Diagnostics, Italy, Category Revenue Share (%), 2009
    • Figure 29: Qiagen N.V., In Vitro Diagnostics, Italy, Market Share (%) by Category, 2009
    • Figure 30: Qiagen N.V., In Vitro Diagnostics, Spain, Category Revenue Share (%), 2009
    • Figure 31: Qiagen N.V., In Vitro Diagnostics, Spain, Market Share (%) by Category, 2009
    • Figure 32: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Category Revenue Share (%), 2009
    • Figure 33: Qiagen N.V., In Vitro Diagnostics, United Kingdom, Market Share (%) by Category, 2009
    • Figure 34: Qiagen N.V., In Vitro Diagnostics, Other Europe, Category Revenue Share (%), 2009
    • Figure 35: Qiagen N.V., In Vitro Diagnostics, Other Europe, Market Share (%) by Category, 2009
    • Figure 36: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Category Revenue Share (%), 2009
    • Figure 37: Qiagen N.V., In Vitro Diagnostics, Middle East and Africa, Market Share (%) by Category, 2009
    • Figure 38: Qiagen N.V., In Vitro Diagnostics, North America, Category Revenue Share (%), 2009
    • Figure 39: Qiagen N.V., In Vitro Diagnostics, North America, Market Share (%) by Category, 2009
    • Figure 40: Qiagen N.V., In Vitro Diagnostics, Canada, Category Revenue Share (%), 2009
    • Figure 41: Qiagen N.V., In Vitro Diagnostics, Canada, Market Share (%) by Category, 2009
    • Figure 42: Qiagen N.V., In Vitro Diagnostics, United States, Category Revenue Share (%), 2009
    • Figure 43: Qiagen N.V., In Vitro Diagnostics, United States, Market Share (%) by Category, 2009
    • Figure 44: Qiagen N.V., In Vitro Diagnostics, South and Central America, Category Revenue Share (%), 2009
    • Figure 45: Qiagen N.V., In Vitro Diagnostics, South and Central America, Market Share (%) by Category, 2009
    • Figure 46: Qiagen N.V., In Vitro Diagnostics, Brazil, Category Revenue Share (%), 2009
    • Figure 47: Qiagen N.V., In Vitro Diagnostics, Brazil, Market Share (%) by Category, 2009
    • Figure 48: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Category Revenue Share (%), 2009
    • Figure 49: Qiagen N.V., In Vitro Diagnostics, Other South and Central America, Market Share (%) by Category, 2009
    • Figure 50: Qiagen N.V., Deals Volume Summary, 2005 to YTD 2010
+44 20 8816 8548

Ask a question about Qiagen N.V.

Enter the characters you see in the picture below
Captcha